YWHAZ (protein for the VVSSIEQK peptide) has recently emerged as an important biomarker to discriminate AD from non-AD cases with cognitive impairment and also predicts individuals with high Tau and low Aβ42 levels58. This evidence concerns the gene MAPT and Cognitive impairment.